OMEROS CORP Lease, Cost
OMEROS CORP (OMER) reported Lease, Cost of $2.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-12
- OMEROS CORP lease, cost for the quarter ending 2026-06-30 was $2.52M, a 0.48% increase year-over-year.
- OMEROS CORP lease, cost for the quarter ending 2026-03-31 was $2.64M, a 5.27% increase year-over-year.
- OMEROS CORP lease, cost for the quarter ending 2025-12-31 was $2.52M, a 11.11% increase year-over-year.
- OMEROS CORP lease, cost for the quarter ending 2025-09-30 was $2.54M, a 11.72% increase year-over-year.
- OMEROS CORP lease, cost for fiscal 2025 was $9.88M, a 7.85% increase from fiscal 2024.
- OMEROS CORP lease, cost for fiscal 2024 was $9.16M, a 2.11% increase from fiscal 2023.
- OMEROS CORP lease, cost for fiscal 2023 was $8.97M, a 4.68% increase from fiscal 2022.
- OMEROS CORP lease, cost for fiscal 2022 was $8.57M, a 17.48% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.52M 10-Q · filed 2026-08-12 | $5.15M 10-Q · filed 2026-08-12 | $7.67M derived: sum of 3 quarters · filed 2026-08-12 | $10.21M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.64M 10-Q · filed 2026-05-13 | $5.16M derived: sum of 2 quarters · filed 2026-05-13 | $7.69M derived: sum of 3 quarters · filed 2026-05-13 | $10.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.05M derived: sum of 2 quarters · filed 2026-03-31 | $7.56M derived: sum of 3 quarters · filed 2026-08-12 | $9.88M 10-K · filed 2026-03-31 |
| 2025-09-30 | $2.54M 10-Q · filed 2025-11-13 | $5.04M derived: sum of 2 quarters · filed 2026-08-12 | $7.36M 10-Q · filed 2025-11-13 | $9.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.50M 10-Q · filed 2026-08-12 | $4.83M 10-Q · filed 2026-08-12 | $7.28M derived: sum of 3 quarters · filed 2026-08-12 | $9.54M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.50M 10-Q · filed 2026-05-13 | $4.77M derived: sum of 2 quarters · filed 2026-05-13 | $7.04M derived: sum of 3 quarters · filed 2026-05-13 | $9.33M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.54M derived: sum of 2 quarters · filed 2026-03-31 | $6.83M derived: sum of 3 quarters · filed 2026-03-31 | $9.16M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.27M 10-Q · filed 2025-11-13 | $4.56M derived: sum of 2 quarters · filed 2025-11-13 | $6.90M 10-Q · filed 2025-11-13 | $9.14M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.29M 10-Q · filed 2025-08-14 | $4.63M 10-Q · filed 2025-08-14 | $6.87M derived: sum of 3 quarters · filed 2025-08-14 | $9.07M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.33M 10-Q · filed 2025-05-15 | $4.58M derived: sum of 2 quarters · filed 2025-05-15 | $6.78M derived: sum of 3 quarters · filed 2025-05-15 | $9.09M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.45M derived: sum of 2 quarters · filed 2025-03-31 | $6.76M derived: sum of 3 quarters · filed 2025-03-31 | $8.97M 10-K · filed 2025-03-31 |
| 2023-09-30 | $2.20M 10-Q · filed 2024-11-13 | $4.51M derived: sum of 2 quarters · filed 2024-11-13 | $6.73M 10-Q · filed 2024-11-13 | $9.06M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $2.31M 10-Q · filed 2024-08-07 | $4.53M 10-Q · filed 2024-08-07 | $6.86M derived: sum of 3 quarters · filed 2024-08-07 | $9.18M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $2.22M 10-Q · filed 2024-05-15 | $4.55M derived: sum of 2 quarters · filed 2024-05-15 | $6.87M derived: sum of 3 quarters · filed 2024-05-15 | $8.96M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $4.66M derived: sum of 2 quarters · filed 2024-04-01 | $6.75M derived: sum of 3 quarters · filed 2024-04-01 | $8.57M 10-K · filed 2024-04-01 |
| 2022-09-30 | $2.32M 10-Q · filed 2023-11-09 | $4.41M derived: sum of 2 quarters · filed 2023-11-09 | $6.24M 10-Q · filed 2023-11-09 | $8.73M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.09M 10-Q · filed 2023-08-09 | $3.92M 10-Q · filed 2023-08-09 | $6.41M derived: sum of 3 quarters · filed 2023-08-09 | $9.07M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.82M 10-Q · filed 2023-05-09 | $4.32M derived: sum of 2 quarters · filed 2023-05-09 | $6.98M derived: sum of 3 quarters · filed 2023-05-09 | $9.86M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $5.16M derived: sum of 2 quarters · filed 2023-03-13 | $8.04M derived: sum of 3 quarters · filed 2023-03-13 | $10.39M 10-K · filed 2023-03-13 |
| 2021-09-30 | $2.66M 10-Q · filed 2022-11-09 | $5.54M derived: sum of 2 quarters · filed 2022-11-09 | $7.89M 10-Q · filed 2022-11-09 | $10.63M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $2.88M 10-Q · filed 2022-08-09 | $5.23M 10-Q · filed 2022-08-09 | $7.97M derived: sum of 3 quarters · filed 2022-08-09 | $10.18M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $2.36M 10-Q · filed 2022-05-10 | $5.08M derived: sum of 2 quarters · filed 2022-05-10 | $7.30M derived: sum of 3 quarters · filed 2022-05-10 | $9.52M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.94M derived: sum of 2 quarters · filed 2022-03-01 | $7.16M derived: sum of 3 quarters · filed 2022-03-01 | $9.31M 10-K · filed 2022-03-01 |
| 2020-09-30 | $2.22M 10-Q · filed 2021-11-09 | $4.44M derived: sum of 2 quarters · filed 2021-11-09 | $6.59M 10-Q · filed 2021-11-09 | $8.95M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $2.22M 10-Q · filed 2021-08-09 | $4.39M 10-Q · filed 2021-08-09 | $6.74M derived: sum of 3 quarters · filed 2021-08-09 | $8.43M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $2.20M 10-Q · filed 2021-05-10 | $4.51M derived: sum of 2 quarters · filed 2021-05-10 | $6.21M derived: sum of 3 quarters · filed 2021-05-10 | $8.09M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $4.00M derived: sum of 2 quarters · filed 2021-03-01 | $5.88M derived: sum of 3 quarters · filed 2021-03-01 | $7.69M 10-K · filed 2021-03-01 |
| 2019-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.58M derived: sum of 2 quarters · filed 2020-11-09 | $5.38M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $3.69M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $1.80M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |